Home/Pipeline/Ultrasensitive Sepsis Diagnostics

Ultrasensitive Sepsis Diagnostics

Sepsis

Development/CommercializationActive

Key Facts

Indication
Sepsis
Phase
Development/Commercialization
Status
Active
Company

About DIANA Biotechnologies

DIANA Biotechnologies is a diversified, venture-backed biotech firm leveraging its proprietary DIANA technology platform to serve the diagnostics and life science research markets. Its core business spans four segments: life science reagents (including a high-potency RNase inhibitor and reverse transcriptase), custom oligonucleotide synthesis, monoclonal antibody development, and drug discovery services like kinase inhibitor profiling. Having established itself as a major COVID-19 test producer in Czechia, the company is now targeting global expansion with its portfolio of PCR solutions and high-value research services.

View full company profile

Other Sepsis Drugs

DrugCompanyPhase
Point of care multiplex sepsis testEDX MedicalLaunching
VB-001VST BioPre-clinical
SIXTIDESepsia TherapeuticsPre-clinical
Injectable Melatonin (IPR-490)PharmamelPhase 2
EXO‑CD24Nano24medPreclinical